References
- Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 2014;13:928–942.
- Mulligan G, Lichter DI, Di Bacco A, et al. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2014;123:632–639.
- Steckel M, Molina-Arcas M, Weigelt B, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012; 22:1227–1245.
- Hoang B, Zhu L, Shi Y, et al. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 2006;107:4484–4490.
- Palumbo A, Gay F, Spencer A, et al. A Phase III study of ASCT Vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance Vs lenalidomide alone in newly diagnosed myeloma patients. ASH Annual Meeting 2013. New Orleans, LA: ASH; 2013.
- Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014;371:906–917.
- Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589–1596.
- Areethamsirikul N, Masih-Khan E, Chu CM, et al. CyBorD induction therapy in clinical practice. Bone Marrow Transpl 2015;50:375–9.
- Chng WJ, Gonzalez-Paz N, Price-Troska T, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008;22:2280–2284.
- Smith D, Armenteros E, Percy L, et al. RAS mutation status and bortezomib therapy for relapsed multiple myeloma. Br J Haematol 2015; doi: 10.1111/bjh.13258. [Epub ahead of print]
- Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467–1473.
- Vij R, Kumar S, Zhang MJ, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transpl 2015;21:335–341.